Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 8Neoplasms 6Head and Neck Neoplasms 6Prostatic Neoplasms 5Oropharyngeal Neoplasms 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Neoplasm Metastasis 4Myasthenia Gravis 4Lymphoma, Large B-Cell, Diffuse 4Cholangiocarcinoma 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3Fatigue 3Endometrial Neoplasms 3Carcinoma 3Breast Neoplasms 3Weight Loss 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Renal Pelvis and Ureter Urothelial Carcinoma × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡